(NASDAQ: IGMS) Igm Biosciences's forecast annual revenue growth rate of 250.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Igm Biosciences's revenue in 2024 is $2,130,000.On average, 5 Wall Street analysts forecast IGMS's revenue for 2024 to be $180,239,679, with the lowest IGMS revenue forecast at $170,481,105, and the highest IGMS revenue forecast at $201,637,997. On average, 3 Wall Street analysts forecast IGMS's revenue for 2025 to be $1,592,117,163, with the lowest IGMS revenue forecast at $881,798,820, and the highest IGMS revenue forecast at $2,865,846,165.
In 2026, IGMS is forecast to generate $5,888,064,654 in revenue, with the lowest revenue forecast at $4,684,703,198 and the highest revenue forecast at $7,671,649,734.